Skip to main content

Advertisement

Table 1 Distribution of insulin products in Bengaluru region, by insulin type, place of manufacture and marketing companies

From: Challenges constraining availability and affordability of insulin in Bengaluru region (Karnataka, India): evidence from a mixed-methods study

a. Private-sector retail (N = 30) and hospital pharmacies (N = 5)
  Products Marketed by Indian companies
(Biocon, Wockhardt, Lupin, Cadila, Nicholas Piramal, Ranbaxy)
Products Marketed by Non-Indian Companies
(Novo Nordisk, Eli Lilly and Sanofi)
Place of Manufacture INDIA Total (N = 109)
Human = 89.0% (n = 97)
Analogue = 10.1% (n = 11)
Porcine = 0.9% (n = 1)
Total (N = 159)
Human = 81.1% (n = 129)
Analogue = 18.2% (n = 29)
Porcine = 0.6% (n = 1)
OUTSIDE INDIA Total (N = 0) Total (N = 72)
Human = 40.3% (n = 29)
Analogue = 59.7% (n = 43)
b. Public-sector hospital pharmacies (n = 5)
  Products Marketed by Indian companies
(Biocon, Lupin, Cadila Healthcare)
Products Marketed by Non-Indian Companies
(Novo Nordisk, Eli Lilly and Sanofi)
Place of Manufacture INDIA Total (N = 11)
Human = 81.8% (n = 9)
Analogue = 18.2% (n = 2)
Total (N = 11)
Human = 90.9% (n = 10)
Analogue = 9.1% (n = 1)
OUTSIDE INDIA Total (N = 0) Total (N = 6)
Human = 33.3% (n = 2)
Analogue = 66.7% (n = 4)
  1. ‘n’ indicates total number of products included in a given segment, irrespective of dosage, strength and delivery device